Novocure stock
NVCRNASDAQNovocure Ltd, HealthcareISIN JE00BYSS4X48
29Score 29 out of 100, Weak
Price and trend
39 / 100
Price history
+3.2% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 21% below it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 28).
The price is 41% below its 52-week high. Largest decline in 11 years: 96% (June 2021 to February 2026).
Chart figures for advanced users
- SMA 50$14.95
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$14.79
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)28
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$10.03
- The lowest closing price of the last twelve months.
- Resistance$19.99
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Novocure Ltd belongs to the Medical (Devices) industry (Switzerland) and, with a market value of $1.37B, is number 51 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $655.35M (up 8.3% year on year) and a loss of $136.23M.
- For fiscal 2026, analysts expect on average revenue of $740.81M (up 13%) and adjusted earnings per share of −$1.08.
Show more
- MEQIRI Score 29 out of 100 (Weak): rank 687 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $463.48M, financial debt $231.55M.Stability 60
Weaknesses
- Loss-makingLoss of $121.73M over the last 12 months.Fundamentals 17
- Turned to a lossEarnings per share from $0.20 in 2020 to −$1.22.Growth 27
- Negative free cash flowFree cash flow −$20.3M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 30 to 29.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 12.9% on the twelve months before. Revenue has grown strongly since 2013, at around 41% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 75%, operating −23%, net −21%.
Debt & balance sheet
latest quarterDebt is moderate; no interest coverage is reported.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 29 Oct 2026EPS reported −$0.09 (expected −$0.23)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 17.6% since 15 Oct 2026.
- Earnings per share
- −$1.08+12.5%
- Revenue
- $740.81M+2.0%
- Earnings per share
- −$0.66+17.6%
- Revenue
- $804.29M−0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −7.2%Novocure raised its 2026 revenue guidance to $736 million to $743 million (12% to 13% growth) and increased its adjusted EBITDA target to $24 million to $34 million.
“We now expect 2026 net revenue between $736 million and $743 million representing 12% to 13% growth. This includes net revenues from Optune Lua and OptunePax collectively, between $30 million and $34 million Gross margin for the quarter was 77% compared to 73% in Q3 of last year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 11 insiders sold, $1.08M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Paravasthu MukundSale
9 Nov 2026, Chief Operating Officer
- Shares
- 3,079
- Price
- $12.86
- Value
- $39,602
- Brackmann ChristophSale
9 Nov 2026, Chief Financial Officer
- Shares
- 7,343
- Price
- $12.86
- Value
- $94,446
- Puri Michal NathSale
2 Nov 2026, Chief Human Resources Officer
- Shares
- 660
- Price
- $13.24
- Value
- $8,738
Show 8 more
- Leonard Frank XSale
4 Jun 2026, Chief Executive Officer
- Shares
- 34,273
- Price
- $17.93
- Value
- $614,635
- Leung GabrielSale
2 Jun 2026, Board
- Shares
- 2,945
- Price
- $15.77
- Value
- $46,445
- Stafford KristinSale
2 Jun 2026, Board
- Shares
- 2,945
- Price
- $15.77
- Value
- $46,445
- Ocean Allyson JSale
2 Jun 2026, Board
- Shares
- 2,945
- Price
- $15.77
- Value
- $46,445
- Scannell Timothy JSale
2 Jun 2026, Board
- Shares
- 2,945
- Price
- $15.77
- Value
- $46,445
- Hilleman Jeryl LSale
2 Jun 2026, Board
- Shares
- 2,945
- Price
- $15.77
- Value
- $46,445
- Vernon W AnthonySale
2 Jun 2026, Board
- Shares
- 2,945
- Price
- $15.77
- Value
- $46,445
- Hung DavidSale
2 Jun 2026, Board
- Shares
- 2,945
- Price
- $15.77
- Value
- $46,445
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Novocure
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 29
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- VitrolifeVITR.ST $1.57B51
- CONMEDCNMD $1.5B68
- EL.En.ELN.MI $1.5B75
- Lumexa Imaging HoldingsLMRI $1.44B48
- PROCEPT BioRoboticsPRCT $1.35B41
- Tandem Diabetes CareTNDM $1.22B43
- Integra LifeSciences HoldingsIART $1.12B48
- Alphatec HoldingsATEC $1.1B34
ETFs that hold Novocure
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.10% | 0.49% | €318.64M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.14% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.12% | 0.40% | €813.42M |
Show 5 more
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.10% | 0.35% | €1.25B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.07% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.04% | 0.43% | €2.5B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.